Video

PD-L1: An Important, But Imperfect Biomarker

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

In the lung cancer space, PD-L1 is not a perfect biomarker, says H. Jack West, M.D., thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center.

PD-L1, a protein that immunotherapy drugs such as Keytruda (pembrolizumab) and Imfinzi (durvalumab) target, may not be as powerful a biomarker as ALK and EGFR. While PD-L1 status is often used to determine which patients should receive certain immunotherapy drugs, clinicians like West have also seen good promising response rates for patients given these agents who test low or negative for PD-L1.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.